130 related articles for article (PubMed ID: 16416553)
1. Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Health News; 2005 Dec; 11(12):13-4. PubMed ID: 16416553
[No Abstract] [Full Text] [Related]
2. Alternative to tamoxifen effective for preventing breast cancer recurrence.
Mayo Clin Womens Healthsource; 2005 May; 9(5):3. PubMed ID: 15891689
[No Abstract] [Full Text] [Related]
3. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Pötter R; Gnant M; Kwasny W; Tausch C; Handl-Zeller L; Pakisch B; Taucher S; Hammer J; Luschin-Ebengreuth G; Schmid M; Sedlmayer F; Stierer M; Reiner G; Kapp K; Hofbauer F; Rottenfusser A; Pöstlberger S; Haider K; Draxler W; Jakesz R;
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):334-40. PubMed ID: 17363187
[TBL] [Abstract][Full Text] [Related]
4. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Panasci LC
J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
[No Abstract] [Full Text] [Related]
5. Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Dizdar O; Harputluoglu H; Altundag K
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651; author reply 1651. PubMed ID: 18035222
[No Abstract] [Full Text] [Related]
6. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
7. New treatment boosts outlook for breast cancer survivors.
Mayo Clin Womens Healthsource; 2004 Mar; 8(3):3. PubMed ID: 15001847
[No Abstract] [Full Text] [Related]
8. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
[TBL] [Abstract][Full Text] [Related]
9. Doctors test drug to prevent cancer in high risk women.
Kmietowicz Z
BMJ; 2003 Oct; 327(7418):768. PubMed ID: 14525859
[No Abstract] [Full Text] [Related]
10. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
11. Stick with tried-and-true breast cancer treatment.
Health News; 2002 Jul; 8(7):5. PubMed ID: 12132502
[No Abstract] [Full Text] [Related]
12. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Hargis JB; Nakajima ST
Cancer Invest; 2006 Mar; 24(2):174-7. PubMed ID: 16537187
[TBL] [Abstract][Full Text] [Related]
13. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
14. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
15. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Tuma RS
J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
[No Abstract] [Full Text] [Related]
16. Searching for the next tamoxifen.
Hobson K
US News World Rep; 2003 Oct; 135(13):44. PubMed ID: 14584460
[No Abstract] [Full Text] [Related]
17. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Dixon JM
Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
[TBL] [Abstract][Full Text] [Related]
18. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Johnston SR
Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
[No Abstract] [Full Text] [Related]
19. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Pharoah PD; Abraham J; Caldas C
J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
[No Abstract] [Full Text] [Related]
20. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Nakamura Y; Ratain MJ; Cox NJ; McLeod HL; Kroetz DL; Flockhart DA
J Natl Cancer Inst; 2012 Aug; 104(16):1264; author reply 1266-8. PubMed ID: 22851270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
